Search Results for: PULMONARY DELIVERY Pulmonary Delivery of
Articles
Parion Sciences Announces Presentation of Clinical Data With Novel Pulmonary Delivery Device October 29, 2016
Parion Sciences, a company dedicated to the development of novel treatments for pulmonary and ocular diseases, recently announced that an...PULMONARY DELIVERY - Pulmonary Delivery of Insulin to Treat Diabetes - A Debacle May 2, 2016
T.R. Shantha, MD, PhD, FACA, says the market for new anti-diabetic therapeutic agents and their painless delivery is enormous and is sure drug companies and research scientists are in a race to develop a safer method other than the pulmonary and oral routes to deliver insulin.
PULMONARY DELIVERY - Afrezza – Another Lesson for Drug Delivery Professionals? February 29, 2016
Josef Bossart, PhD, believes Mannkind’s recent announcement that Sanofi has decided to return the marketing rights for Afrezza may not exactly be history repeating itself, but it certainly feels as though it rhymes.
MannKind to Proceed With Phase 1 Nintedanib DPI Study for Pulmonary Fibrotic Diseases April 30, 2024
MannKind Corporation recently announced it will proceed with a first-in-human Phase 1 study of nintedanib DPI (MNKD-201) for pulmonary fibrotic...Bespak Confirms Inhaled & Nasal Drug Delivery Business Separation From Recipharm April 2, 2024
Spin-out unites three sites to create a leading global CDMO as further significant investments announced at Holmes Chapel site….
Kindeva Drug Delivery Launches New Analytical Services Global Business Unit January 31, 2024
Kindeva Drug Delivery recently announced the expansion of its analytical services capabilities — launching a new global business unit offering integrated...Kindeva Drug Delivery Acquires Summit Biosciences, a Specialized Nasal Drug Development & Manufacturing Organization January 18, 2024
Kindeva Drug Delivery recently announced it has acquired Summit Biosciences Inc., an intranasal drug delivery contract development and manufacturing organization, from its founding….
Aerovate Therapeutics Announces Simultaneous Completion of Enrollment in Phase 2b Portion & Enrollment of First Patient Into Phase 3 Trial Evaluating AV-101 for the Treatment of Pulmonary Arterial Hypertension November 21, 2023
Aerovate Therapeutics, Inc. recently announced the Phase 2b portion of the Inhaled iMatinib Pulmonary Arterial Hypertension Clinical Trial (IMPAHCT) Phase...Kindeva Drug Delivery, Chiesi Group & H&T Presspart Announce Strategic Partnership for Dose Counter Technology Production July 11, 2023
Kindeva Drug Delivery and H&T Presspart are partnering with Chiesi Group for the installation of a production line for dose counter (DC) and dose indicator (DI) devices. Combining the specific….
FORMULATION FORUM - PLGA – A Versatile Copolymer for Design & Development of Nanoparticles for Drug Delivery June 5, 2023
Jim Huang, PhD, and Shaukat Ali, PhD, focus on the chemistry, properties, applications, and regulatory aspects of PLGA, and the future trends in the industry, especially those requiring the development of long-acting injectables for the treatment of a variety of rare diseases and for life cycle management.
Arrowhead Pharmaceuticals’ Proprietary Pulmonary TRiM Platform Achieves High Levels of Target Gene Knockdown & Long Duration of Effect April 25, 2023
Interim Results from Ongoing ARO-RAGE Phase 1/2 Study Demonstrate up to 90% Serum sRAGE Reduction with Mean Maximum Reduction of 80% after Two Doses….
Apellis Expands R&D Collaboration With Affilogic to Develop Targeted Complement Therapies for Delivery into the Brain June 22, 2022
Apellis Pharmaceuticals, Inc. and Affilogic recently announced the companies have expanded their research and development (R&D) collaboration, which was initially formed in 2018, to include the development of Nanofitins….
NASAL DELIVERY - Improving Nasal Drug Delivery With Permeation Enhancing Technology March 1, 2022
Stuart Madden, PhD, focuses on the use of alkylsaccharides as absorption enhancers for nasal delivery of a wide range of drug types.
FORMULATION FORUM - Formulation & Process of Lipid Nanoparticles for Delivery of Small Molecules & Biologicals January 17, 2022
Jim Huang, PhD, explains how recently, lipid nanoparticles have emerged as a drug delivery system for biologicals, especially for the COVID-19 mRNA vaccines in which LNPs play a vital role in transporting mRNA into the target cells.
ORGAN-ON-A-CHIP - A Novel Way to Accurately Test Delivery of Non-Standard Formulations January 17, 2022
David Hughes, PhD, says ultimately, the goal of OOC technology is to improve the translatability of data between the lab and the clinic. Through a lung-on-a-chip approach, it is possible to recreate the histoarchitecture, phenotype, and function of bronchial and alveolar areas of the lung.
Innovative Inhaled Drug Delivery Developer Aerami Therapeutics to Merge With Special Purpose Acquisition Company FoxWayne Enterprises Acquisition Corp. to Become Public Company December 7, 2021
Aerami Therapeutics Holdings, Inc. and FoxWayne Enterprises Acquisition Corp. recently announced they have entered into a definitive business combination agreement…..
Aerami Therapeutics Announces Orphan Drug Designation for Imatinib for the Treatment of Pulmonary Arterial Hypertension August 31, 2021
Aerami Therapeutics, Inc. recently announced the US FDA has granted the company orphan drug designation for imatinib for treatment of...SPECIAL FEATURE - Injection Devices: Designing Simplicity, Safety & Adherence Into One Delivery System August 26, 2021
Contributor Cindy Dubin, in this annual report, speaks with industry innovators and takes a deep dive into the myriad injectables that are currently in development or recently introduced to the market.
2021 Respiratory Drug Development eBook – The Three Cs Driving Respiratory Drug Delivery June 29, 2021
In this third annual Drug Development & Delivery Respiratory eBook, several companies discuss what they are currently working on to propel the respiratory sector.
INHALATION DELIVERY - Inhaled Drug Development: Optimizing Delivery March 29, 2021
Sandy Munro, PhD, Nikki Willis, and Geraldine Venthoye, PhD, believe selecting the delivery device/platform on the basis of patient needs, nature of disease, and opportunities for accelerating the proof-of-concept or early clinical stages by using fast-to-clinic approaches can help to accelerate the project through later-stage development by combining the approach with seamless scalability, designing in manufacturability, and an appropriate manufacturing strategy.